Download the Article
Description: The article discusses the transition to low GWP propellants in the respiratory drug delivery sector as current high-GWP variants are phased out. The leading propellant options for the next generation of low GWP MDIs ( metered dose inhalers) are HFA 152a and HFO 1234ze from the hydro-fluoroolefin family. The article highlights the need for these new options to be thoroughly assessed using strict criteria, with robust evidence that they deliver continuity of both functional and pharmaceutical performance while addressing concerns in the areas of toxicity, flammability, and environmental impact, especially their Global Warming potential. Aptar Pharma’s role in this transition is also discussed, with the company taking a holistic approach to drug delivery to enable pharma partners to answer such questions by drawing on the specialist expertise within its broad operational portfolio. The article concludes by discussing the future of MDIs in delivering both improved environmental performance and better patient outcomes.
